NCT06365619

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

Phase II Study of Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: University of Utah · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to study the impact of Neoadjuvant ipilimumab and nivolumab for melanoma patients that had recurrence during or after adjuvant anti-PD-1 therapy. Participants will receive 2 cycles of treatment prior to their standard of care surgery. After surgery participants will receive standard of care adjuvant therapy and be followed for response.

Conditions

• Melanoma

Interventions

Type	Name	Description
DRUG	Ipilimumab	Two cycles of neoadjuvant ipilimumab prior to surgical resection.
DRUG	Nivolumab	two cycles of neoadjuvant nivolumab prior to surgical resection.

Timeline

• Start date: 2026-02-01
• Primary completion: 2026-08-01
• Completion: 2029-08-01
• First posted: 2024-04-15
• Last updated: 2026-01-29

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study